Literature DB >> 30567142

Management of hypertriglyceridaemic pancreatitis in the acute setting and review of literature.

Suhaniya Samarasinghe1, Parizad Avari2, Karim Meeran2, Jaimini Cegla2.   

Abstract

Acute pancreatitis (AP) is a potentially life-threatening complication of severe hypertriglyceridaemia, which is the third most common cause of AP after gallstone disease and alcohol excess. Standard therapy involves the use of lipid-lowering agents, low-molecular-weight heparin and insulin infusion. In some cases, when standard medical therapies fail, non-pharmacological methods based on the removal of triglycerides with therapeutic plasma exchange can provide positive results in the acute phase. There are currently no guidelines covering management in the acute phase, however, these approaches should be considered in severe or very severe hypertriglyceridaemia. Here, we report the case of a 37-year-old man with recurrent AP due to hypertriglyceridaemia and review the literature. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  endocrine system; lipid disorders; pancreatitis

Mesh:

Substances:

Year:  2018        PMID: 30567142     DOI: 10.1136/bcr-2018-227594

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Management of Hypertriglyceridemia-Induced Acute Pancreatitis in a Nondiabetic Patient.

Authors:  Jamie M Reed; Breann M Hogan; Navine Nasser-Ghodsi; Conor G Loftus
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-02-26

2.  Management of Hypertriglyceridemia-Induced Acute Pancreatitis in a Nondiabetic Patient.

Authors:  Jamie M Reed; Breann M Hogan; Navine Nasser-Ghodsi; Conor G Loftus
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-04-08

3.  An Uncommon Cause of Chest Pain: Hypertriglyceridemia-Induced Pancreatitis.

Authors:  Brian J Fasolka; Leon L Chen
Journal:  Crit Care Nurs Q       Date:  2020 Jan/Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.